Welcome to our dedicated page for Azenta news (Ticker: AZTA), a resource for investors and traders seeking the latest updates and insights on Azenta stock.
Azenta, Inc. provides life sciences solutions focused on cold-chain sample management, automated storage, consumables, informatics, repository services and multiomics offerings. Its updates commonly cover the Sample Management Solutions and Multiomics businesses, including genomic services, gene synthesis execution, sample storage, high-throughput processing and branded products such as GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro and Barkey.
Azenta news also includes quarterly operating results, guidance updates, long-range planning, governance and leadership changes, customer and research partnerships, and acquisition activity. The completed acquisition of UK Biocentre expanded the company’s sample management, sample storage and processing capabilities in the United Kingdom and added a European operational hub for its Sample Repository Services business.
Azenta (Nasdaq: AZTA) reported third quarter fiscal 2026 revenue from continuing operations of $161 million, up 12% year over year and 11% sequentially. Organic revenue grew 9%, with Sample Management Solutions at $88 million (14% YoY, 9% organic) and Multiomics at $73 million (10% YoY, 8% organic).
GAAP operating loss from continuing operations was $4.2 million with a (2.6%) margin, and diluted EPS from continuing operations was ($0.03), while total diluted EPS, including discontinued B Medical Systems, was $0.05. Adjusted EBITDA from continuing operations was $18.5 million (11.4% margin) and non-GAAP diluted EPS was $0.16. Azenta ended the quarter with $529 million in cash and marketable securities, generated $1 million in operating cash flow and recorded negative free cash flow of $5 million. Under its $250 million repurchase program, it has repurchased 2.3 million shares for $50 million to date.
Cabot (NYSE: CBT) announced that President and CEO Sean Keohane will retire and leave the Board effective September 30, 2026. Executive Vice President, CFO and Head of Corporate Strategy Erica McLaughlin has been elected to become President, CEO and director effective October 1, 2026. Keohane will serve in an advisory role through year-end 2026, and Cabot has begun a search for a new CFO.
Azenta (Nasdaq: AZTA) plans to release its fiscal third quarter 2026 earnings, for the period ended June 30, 2026, on Tuesday, August 4, 2026, after the market close.
The company will hold a conference call and live webcast to discuss results on Wednesday, August 5, 2026, at 8:30 a.m. Eastern Time, with live and replay access via its investor relations website.
Azenta (Nasdaq: AZTA) completed the sale of its B Medical Systems business to Thelema S.à r.l. on July 1, 2026. The deal, first announced December 29, 2025, had a fixed cash purchase price of $63 million.
According to Azenta, $35 million of the price was funded via a short-term secured vendor loan from an Azenta subsidiary to Thelema. Management states the divestiture supports a strategy to simplify the portfolio, focus on core life sciences businesses, and enhance financial flexibility.
Azenta (Nasdaq: AZTA) published its 2025 ESG report covering the fiscal year ended September 30, 2025. The report outlines progress across environmental protection, social impact, and responsible operations.
Highlights include first-time disclosure of Scope 3 GHG emissions, submission of near-term reduction targets to the Science Based Targets initiative, about 40% Scope 1 and 2 reduction vs FY2022, sourcing 72% renewable electricity, expanded sustainable products like BioArc Ultra, global well-being programs for employees, an updated ERM framework with Board approval, and broader adoption of the Azenta Business System to improve quality and reduce waste.
Azenta (Nasdaq: AZTA) reported Q2 FY2026 continuing‑operations revenue of $145 million (1% YoY) and adjusted EBITDA of $7.8 million (5.4% margin). GAAP operating loss was $165.8 million, including a $149 million goodwill impairment. Fiscal 2026 revenue guidance is $603–$621 million; organic revenue now expected down ~2% to up 1% and long‑range plan extended to 2029.
Azenta (Nasdaq: AZTA) will announce fiscal second quarter 2026 results for the period ended March 31, 2026 on Wednesday, May 6, 2026 before market open. The company will host a conference call and live webcast on May 6 at 8:30 a.m. ET. A replay will be available beginning 8:30 a.m. ET on May 7, 2026. Webcast access: https://investors.azenta.com/events.
Azenta (Nasdaq: AZTA) named Trey Martin President of its Multiomics business, effective April 6, 2026, to accelerate execution of its Multiomics long-range plan and scale global gene synthesis capabilities. Ginger Zhou will step down as president and serve as an advisor through November 2026 to ensure continuity.
The move emphasizes operational excellence, commercial discipline, and profitable growth across Azenta's integrated Multiomics platform, with Martin reporting to CEO John Marotta and bringing extensive genomics and synthesis experience from Maravai and Danaher/IDT.
Azenta (Nasdaq: AZTA) acquired UK Biocentre Limited to expand biorepository and sample-management capabilities across Europe.
The deal consideration was GBP 20.5 million (net of cash, including up to GBP 1.8 million contingent). UK Biocentre had ~GBP 15.3 million revenue for the 12 months ended Sept 30, 2025. Azenta expects ~35bps dilution to 2026 Adjusted EBITDA margin and anticipates accretion to 2027–2028 organic revenue and margin targets. Azenta plans to deploy its 16-million-sample BioArc™ Ultra later in the year. A transaction webcast is scheduled for March 10, 2026.
Azenta (Nasdaq: AZTA) will participate in the Raymond James 47th Annual Institutional Investor Conference on March 3, 2026. Management will present beginning at 4:00 PM ET. A live webcast is available via the Azenta investor relations site and a replay will be posted after the event.